Advertisement

Topics

Amygdala Initiates Phase Ib Clinical Study Of ANS-6637, The First-In-Class Selective ALDH2 Inhibitor In Development As A Treatment For Substance Use Disorder

20:00 EDT 31 Jul 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Amygdala Initiates Phase Ib Clinical Study Of ANS-6637, The First-In-Class Selective ALDH2 Inhibitor In Development As A Treatment For Substance Use Disorder

NEXT ARTICLE

More From BioPortfolio on "Amygdala Initiates Phase Ib Clinical Study Of ANS-6637, The First-In-Class Selective ALDH2 Inhibitor In Development As A Treatment For Substance Use Disorder"

Quick Search
Advertisement